Zanzalintinib is an orally active, ATP-competitive multi-receptor tyrosine kinase inhibitor used for preclinical research. It targets MET, VEGFR2, AXL, and MER, with reported cell-based IC50s in the low nanomolar range, and is provided as a research-grade compound (molecular formula C29H25FN4O5; MW 528.53). This compound is for laboratory research only and is not intended for human use.
- Multi-kinase activity against MET, VEGFR2, AXL, and MER.
- Potent cellular activity with low-nanomolar IC50 values.
- Suitable for kinase inhibition and cell-based assays.
- High purity for research applications (>98% reported).
- Stable under recommended storage when protected from light.
- Provided as a solid for preparation of stock solutions.